New approach for treatment of diabetic ulcer

Al Falah, Walaa (2020-02-17)

Diabetic foot ulcer (DFU) is a localized injury to the skin and/or underlying tissue of the foot of patients with diabetes mellitus; the occurrence of foot problems increases the risk of amputation and death of these patients. A number of studies have shown that diabetic patients have a decreased amount of growth factor concentrations, mainly epidermal growth factor (EGF). Naturally found in the body, EGF stimulate and promote cell growth and regeneration by binding to its receptors -epidermal growth factor receptors (EGFR). Epidermal growth factor acts as a healing agent in that it speeds wound recovery by triggering the synthesis of collagen, elastin and hyaluronic acid


Diabetic foot ulcer is a principal diabetic complication. It has been shown that diabetic patients have decreased growth factor concentrations in their tissues, particularly epidermal growth factor. Growth factor shortage impairs wound healing, which leads to chronic non healing wounds and sometimes eventual amputation. Ischemic diabetic foot ulcer is the most difficult to treat and confers the highest amputation risk. but we found new approach for treatment of diabetic ulcer, Injecting epidermal growth factor deep into the wound bottom and contours encourages a more effective pharmacodynamic response in terms of granulation tissue growth and wound closure. Epidermal growth factor injected into the ulcer matrix may also result in association with extracellular matrix proteins, thus enhancing cell proliferation and migration. Heberprot-P is an innovative Cuban product containing recombinant human epidermal growth factor for peri- and intra-lesional infiltration; evidence reveals it accelerates healing of deep and complex ulcers, both ischemic and neuropathic, and reduces diabetes-related amputations

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States